Immune activation via GM-CSF–secreting allogeneic tumor cell

Immune activation via GM-CSF–secreting allogeneic tumor cells refers to a cancer immunotherapy approach where whole tumor cells are genetically engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). These modified cells are typically irradiated so they cannot proliferate but can still release GM-CSF after administration. The secreted cytokine acts locally at the vaccination site to recruit and activate antigen-presenting myeloid cells—primarily dendritic cells—which then process and present a broad array of endogenous tumor antigens from the injected vaccine. This leads to enhanced priming of cytotoxic T lymphocytes capable of recognizing and attacking patient tumors expressing similar antigens. This strategy is exemplified by vaccines such as GVAX. The approach leverages both the broad antigenicity provided by whole-tumor lysates/cells and the potent immunostimulatory properties of GM-CSF. While generally well tolerated, there are concerns about possible pro-inflammatory side effects if excessive or chronic local cytokine production occurs. This method is not a single molecular target but rather an engineered cellular product designed for therapeutic immune modulation in oncology settings[1][2].

Other names

GM-CSF–secreting tumor cell vaccineGVAXGranulocyte-macrophage colony-stimulating factor–secreting allogeneic tumor cell vaccine

Induction of antitumor immunity by secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) from engineered allogeneic tumor cells, which recruits and activates antigen-presenting cells such as dendritic cells and macrophages[1][2]. Enhancement of antigen cross-presentation to T-cells, leading to cytotoxic T lymphocyte responses against tumors[1][2].